Options for pegfilgrastim administration | Potential characteristics |
---|---|
Administration on the same day of myelosuppressive chemotherapy within a clinic, by a health professional. | ▪ Not having to return to the clinic 24 h after chemotherapy to receive the injection ▪ Not having to return to the clinic 48–72 h after chemotherapy to receive the injection. ▪ No need to place the body injector for Neulastim®. |
Administered when the patient returns to the clinic 24 h after myelosuppressive chemotherapy, specifically for the purpose of receiving an injection of pegfilgrastim, by a healthcare provider. | ▪ Not having to return to the clinic 48–72 h after chemotherapy to receive the injection. ▪ No need to place the body injector for Neulastim®. |
Administered when the patient returns to the clinic 48–72 h after myelosuppressive chemotherapy, specifically for receiving an injection of pegfilgrastim, by a healthcare provider. | ▪ Not having to return to the clinic 24 h after chemotherapy to receive the injection ▪ No need to place the body injector for Neulastim®. |
Administration at home using the Onpro Neulastim®™ kit (OBI) that has been attached to the patient’s arm or abdomen at the clinic; approximately 27 h (a little more than 1 day) after myelosuppressive chemotherapy. | ▪ Not having to return to the clinic 24 h after chemotherapy to receive the injection ▪ Not having to return to the clinic 48–72 h after chemotherapy to receive the injection. |